INTRODUCTION
It was estimated that 52,610 new cases of head and neck cancer and 11,400 deaths would occur in 2012 in the United States. 1 Recent advances in the multimodality treatment of this disease have significantly improved organ preservation and quality of life. 2, 3 Modest improvement in 5-year survival for all sites has been largely because of improved outcomes in patients with cancer of the oropharynx, consistent with the evolving changes in etiology for that site. 4 In spite of these advances, between 15% and 50% of patients treated with multimodality treatment recur within 2 years, [5] [6] [7] [8] [9] most commonly at the primary site or in the neck, and outcomes for these patients are poor with currently available treatment options. Therefore, there is an urgent need to develop novel, effective therapies for patients with refractory head and neck cancer. Because the pattern of recurrence for head and neck cancer is predominantly locoregional, this disease serves as a model for tumor-directed strategies aiming at improving local control, either alone or in combination with systemic therapies.
Oncolytic virotherapy is a strategy that exploits the natural ability of viral vectors to preferentially infect, replicate, and induce potent cytotoxicity in cancer over non-cancer cells. 10 Many oncolytic viral vectors can be genetically modified to carry genes that improve safety or antitumor effects. Examples include adenovirus, herpes simplex virus, reovirus, measles virus, and vesicular stomatitis virus, among others. 10, 11 Several of the above viral vectors are being evaluated in clinical trials in patients with advanced head and neck cancer.
Vesicular stomatitis virus (VSV) is an RNA virus that belongs to the family of rhabdoviridae. 12 It induces potent in vitro and in vivo tumor cytotoxic effects, and its efficacy has been tested in a number of xenograft and syngeneic models. Preclinical studies have demonstrated activity of recombinant VSV alone or in combination with chemotherapy in murine and human models of squamous cell carcinoma (SCC) of the head and neck. [13] [14] [15] VSVinduced neurotoxicity, however, is dose limiting, 16, 17 which limits the clinical development efforts of this agent. To attenuate VSV toxicity, we have developed a recombinant VSV that carries the gene encoding interferon beta (vesicular stomatitis virus expressing interferon-b [VSV-IFN-b]), which has shown improved safety profile while keeping its in vitro and in vivo oncolytic effects. 18 In addition, interferon-b (IFN-b) expression in the tumors may improve the antitumor efficacy because of intrinsic antiproliferative effects of IFN. 19, 20 VSV-h-IFN-b (expressing human interferon-b) is currently being developed as an oncolytic agent against hepatocellular carcinoma (clinicaltrials.gov NCT01628640). In this report, we present the results of preclinical studies characterizing the safety, biodistribution, antiviral antibody response, and antitumor efficacy of VSV-IFN-b in a syngeneic, immunocompetent rat model of SCC, in preparation for clinical evaluation of this viral vector in human SCC of the head and neck.
MATERIALS AND METHODS

Cell culture
Mouse (SCC-VII) and rat (FAT-7) SCC cell lines were obtained from ATCC (Manassas, VA) and maintained in Dulbecco modified Eagle's medium (DMEM) with 10% fetal bovine serum (FBS), 1% penicillin, streptomycin (1% P/S), Ham's F12K medium with 0.01 mg/mL insulin, 250 ng/mL hydrocortisone, 0.0025 mg/mL transferrin, and 10% FBS, respectively. BHK-21 cells were maintained in DMEM supplemented with 10% FBS (MediaTech, Manassas, VA), 100 U of penicillin G/mL, 100 U of streptomycin/mL, and 0.25 lg of amphotericin B. All cells were kept at 37 C in a humidified 5% CO 2 incubator.
Virus generation and expansion
Recombinant VSVs expressing human (VSV-h-IFN-b), mouse (VSV-m-IFN-b) and rat (VSV-r-IFN-b), were generated and propagated, as previously described. 18, 21 Viruses were frozen at -65 C or lower until use. Viruses were diluted in sterile normal saline to the desired concentration and kept on ice until use for in vitro and in vivo experiments. Virus titer was verified by 50% tissue culture infective dose (TCID 50 ) titration on VERO or BHK-21 cells (for in vivo safety and biodistribution experiments) or by plaque dilution (for in vitro and in vivo efficacy experiments), as previously described.
22,23
Assessment of in vitro cytopathic effects
Cells were plated in 6-well plates (1 3 10 6 /well) and then infected with VSV-r/m/h-IFN-b at different multiplicity of infection (MOI), depending on the experiment, for 1 hour at 37 C in 2 mL of Opti-MEM reduced serum media (Invitrogen, Carlsbad, CA). Fresh media was then added for the respective cells and they were incubated for 24, 48, or 72 hours postinfection. At each time point, cell viability and cytotoxicity were measured using the Trypan blue exclusion analysis. [24] [25] [26] [27] Cytotoxicity experiments were performed in normoxic and hypoxic conditions. Hypoxic conditions (0.3% O 2 ) were generated with the use of a hypoxia chamber (Coy Lab Products, Grass Lake, MI).
Western blotting
FAT-7 cells and SCC-VII cells (1 3 10 6 ) were seeded in a 6-well plate and infected and incubated with viruses at 1 hour and at an MOI of 5 and 10 PFU per cell and incubated for 24 hours in serum-free Opti-MEM (Invitrogen). Cell supernatants were obtained, and protein concentration was determined using a Bio-Rad protein assay (Bio-Rad, Hercules, CA). A total of 20 lg of supernatant protein was then separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to a 0.2 lM polyvinylidene fluoride membrane (Bio-Rad). Polyclonal rabbit antibodies against rat or mouse-IFN-b (Research Diagnostics, Flanders, NJ) were used as the primary antibodies. Horseradish peroxidase-conjugated antirabbit or anti-mouse was used as a secondary antibody (Promega, Madison, WI) and detected by enhanced chemiluminescence (Pierce, Rockford, IL). 
In vivo studies
In vivo safety and biodistribution studies
Studies were performed in tumor and non-tumorbearing rats, to assess the toxicity of VSV-r-IFN-b or VSV-h-IFN-b at different dose levels after intratumoral or subcutaneous administration of the test agent. Studies in non-tumor-bearing rats assessed the safety of escalating doses of VSV-h-IFN-b (n 5 9), and the safety of VSV-h-IFN-b or VSV-r-IFN-b at a fixed dose, compared to saline administration (n 5 8). In tumor-free rats, the test agent was administered (in a total volume of 50 lL) s.c. below the right jaw line. Studies in tumor-bearing rats assessed the safety, biodistribution, and antibody formation of escalating doses of VSV-r-IFN-b (n 5 38) or VSV-h-IFN-b (n 5 24). Rats were randomized into different treatment groups (equal number of males and females) when tumors reached a diameter of approximately 5 mm. The test agent was administered intratumorally in a total volume of 50 lL.
All rats were observed for toxicity throughout the duration of the study. To assess treatment-related toxicity and biodistribution, groups of rats were euthanized on day 2 and on days 28 or 29, and tumors and organs were harvested for analysis of toxicity and viral replication. Blood was extracted from rats on day 2 (jugular vein) and on days 28 or 29 (cardiac puncture) for determination of blood counts, chemistry, viremia, and antibody production, as described below.
Anti-vesicular stomatitis virus antibody enzyme-linked immunosorbent assay
Serum samples were taken from the rats on days 2 and 28 or 29 after virus administration. Carbonate bicarbonate buffer (Sigma-Aldrich, St. Louis, MO) was used as coating buffer. VSV-r/h-IFN-b (titer 2.4 3 10 11 TCID 50 /mL) was diluted 1:10,000. MaxiSorp (Nunc) plates were coated at 100 lL per well and placed at 2 C to 8 C overnight. The plates were washed with 0.1% Tween 20 (BioRad #170-3561) in PBS (Bio-Rad), 200 lL per well, 3 times. A total of 10X casein (Vector Laboratories, Cambridgeshire, UK) was diluted to 1X and added to plates to block at 100 lL per well for 2 hours at room temperature. Serum samples were diluted 1:500 in PBS and added in duplicate at 100 lL per well. The plates were incubated at room temperature for 1 hour. The plates were washed, as previously described. Biotin rabbit anti-rat (Dako, Carpinteria, CA) was diluted in PBS to 1:1000 and added at 100 lL per well. The plates were incubated at room temperature for 1 hour. The plates were washed, as previously described. Peroxidase-labeled streptavidin (KPL) was diluted in PBS at 1:1000 and added at 100 lL per well for 1 hour at room temperature. The plates were washed, as previously described. TMB substrate (KPL) was prepared immediately before use. A total of 100 lL of TMB was added to each well. The plates were incubated at room temperature for approximately 10 minutes while color developed. A total of 1N HCl was added to each well at 100 lL to stop the reaction. The plates were read at 450 nm.
Infectious virus recovery
Samples were collected, as explained above, and frozen at 65 C until analysis. Tissues were weighed and homogenized in 3 volumes (w/v) of Opti-MEM (Invitrogen) utilizing mechanical crushing and a single freeze-thaw cycle. The supernatant was clarified by centrifugation and 10-fold serial dilutions of samples were prepared in Opti-MEM. Aliquots (50 lL) of each dilution were placed in 96-well plates containing BHK-21 cells (American Type Culture Collection [ATCC]) and TCID 50 titrations were performed, as described previously. 28 TCID 50 calculations were normalized per gram of tissue. The determined limit of detection (LOD) for the assay was 1.9 3 10 2 TCID 50 /gram of tissue. The determined limit of quantification (LOQ) for the assay was 1.9 3 10 3 TCID 50 /gram of tissue. Samples that were above the LOD but below the LOQ were determined to be putative positives, and are notated as less than or equal to the calculated value.
RNA isolation from tissues and quantitative reverse-transcriptase polymerase chain reaction for vesicular stomatitis virus nucleoprotein
Sample tissues and blood were RNAlater-preserved (Applied Biosystems, Foster City, CA) and were processed for RNA isolation and quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR) for VSV-nucleoprotein (VSV-N) RNA. All tissues were homogenized for 2 minutes (20-30 Hz twice) using a single 5 mm stainless steel bead (Qiagen, Limborg, UK) in the TissueLyser II instrument (Qiagen) equipped with 2 3 24 adapter set (Qiagen) and spun through QIAShredders (Qiagen), in accord with the manufacturer's instructions. Tumor, liver, lung, spleen, ovaries, testes, brain, and spinal cord were processed in accord with the manufacturer's instructions using the RNeasy Plus Mini Kit or RNeasy Lipid Tissue Mini Kit (Qiagen). The optional RNase-free DNase set (Qiagen) was used in accord with the manufacturer's instructions with the remaining RNA isolation kits. The qRT-PCR for VSV-N analysis was performed as previously described. 21 All samples and standards were run in triplicate. Samples were quantitated by comparison with a standard curve generated by amplification of 432-bp in vitro-transcribed RNA (MAXIscript SP6 kit; Applied Biosystems) encoding a 298-base portion of the VSV nucleocapsid gene (bases 972-1269) cloned in pCRII-TOPO (Invitrogen).
In vivo efficacy studies FAT-7 tumors were established as outlined above. When tumors reached approximately 0.5 cm in diameter, rats were randomized into controls (PBS) or treatment groups (n 5 10 per group). Depending on the in vivo experiment, different doses of viral agent (diluted in 100 lL PBS) or vehicle were administered either intratumorally or IV. For all in vivo experiments, rats were euthanized when any one of the following criteria were met: (1) neurotoxicity, (2) tumor volume exceeded 10% of body weight, (3) ulcerated tumors, (4) if the animal was unable to reach food or water, or (5) had 15% body weight loss. Both tumor progression and time to euthanization were analyzed.
Statistical analyses
Data are presented as means 6 SD (for in vitro studies) or SEM (for in vivo studies). In vitro experiments were performed in triplicate and repeated twice, unless otherwise specified. Differences in means among groups were compared by analysis of variance, and pairwise comparisons were performed using the t test or the TukeyKramer method. Survival curves were generated using the Kaplan-Meier method and compared using the log-rank test. Differences were considered statistically significant at p < .05.
RESULTS
In vitro cytotoxicity, viral replication and gene expression of recombinant vesicular stomatitis virus-rat-interferon-b and vesicular stomatitis virus-mouse-interferon-b on rat and mouse squamous cell carcinoma cell lines Rat (FAT-7) and mouse (SCC-VII) SCC cells were exposed to VSV-r/m-IFN-b at different MOIs and viability/cytotoxicity was assessed at 24-, 48-, and 72-hour time points. VSV-r/m-IFN-b significantly inhibited viability and induced cytotoxicity in a dose-and time-dependent manner in FAT-7 ( Figures 1A and 1B) and SCC-VII cells (Figures 2A and 2B ). VSV-r-IFN-b (MOI 5 1) inhibited FAT-7 viability by 80% (p < .0001) and induced cytotoxicity (70% vs 6% in controls; p< .0001), at 48 hours (Figures 1A and 1B) . Similar results were observed in SCC-VII cells, in which VSV-m-IFN-b (MOI 5 1) resulted in a 79.5% reduction in viability at 48 hours and significant cytotoxic effects (56.7% vs 5.2%), compared with controls (p < .0001 for both; Figures 2A and 2B ). Statistically significant increased cytotoxicity was observed at MOIs of 0.01 and higher, both in FAT-7 (p 5 .0019) and in SCC-VII cells (p 5 .013). The cytotoxic effects were observed as early as 24 hours after infection and were prominent at 48 hours and later in the rat and mouse SCC cell lines ( Figures 1C and 2C) . Hypoxia did not significantly affect viral-induced cytotoxicity in FAT-7 and SCC-VII cells ( Figures 1D and 2D , respectively) and did not affect in vitro viral replication (data not shown).
Next, replication of VSV-r/m-IFN-b in rodent cell lines was assessed at different time points after infection. 29 As shown in Figures 1E and 2E , rat and mouse viruses efficiently replicated in FAT-7 and SCC-VII cells, respectively, as evaluated by determination of viral titers 24 and 48 hours after viral infection. Viral titers at 48 hours postinfection were 5.43 3 10 9 in FAT-7 cells ( Figure 1E ) versus 3.71 3 10 9 in SCC-VII cells ( Figure 2E ). Viralinduced transgene expression was confirmed by determination of IFN-b protein in the conditioned media of FAT-7 and SCC-VII cells by Western blot 24 hours after viral infection (MOI 5 and 10; Figures 1F and 2F) .
The above results suggest that both mouse and rat SCC cells are susceptible to VSV-IFN-b cytopathic effects, and both are permissive to viral replication. We observed, however, that FAT-7 cells were associated with more efficient viral replication and cytotoxic effects than SCC-VII cells ( Figures 1B and 1E vs Figures 2B and 2E) . We then assessed differences in viability, cytotoxicity, and viral replication between recombinant VSV vectors expressing human and rat IFN-b in FAT-7 cell lines. As seen in Figures 3A and 3B, the cytotoxic effects of VSV-r-IFN-b and VSV-h-IFN-b were comparable (p 5 NS). Similarly, FAT-7 cells were permissive to viral replication of both the human and rat variants of the virus, but titers of VSV-h-IFN-b were higher than VSV-r-IFN-b ( Figure 3C ).
In vivo safety and virus biodistribution after local administration of vesicular stomatitis virus-ratinterferon-b or vesicular stomatitis virus-humaninterferon-b in tumor-and non-tumor-bearing rats FAT-7 tumors were established in immunocompetent Fisher-344 rats, as outlined in the Materials and Methods tumor-bearing rats. We observed that after s.c. injection of 10 10 VSV-r-IFN-b in non-tumor-bearing rats, a small focal subcutaneous cellulitis was observed, which resolved spontaneously. No significant weight changes were observed in treated animals.
To determine the presence of infectious virus in tumor or non-tumor tissues after VSV-r-IFN-b, administration, a group of rats (n 5 8) was given intratumoral VSV-r-IFNb, and brain, spleen, and tumor samples were collected 48 hours after treatment. No virus was detected in brain or spleen samples, whereas infectious virus was detected in 5 of 8 tumor samples in rats treated with VSV-r-IFN-b ( Figure 4A ). Infectious viral particles were undetectable (below limit of detection), at day 28 or 29 of treatment (not shown). Tissue biodistribution was further characterized by determination of VSV-N RNA by qRT-PCR in rats treated with the highest dose of oncolytic virus (10 10 TCID 50 ). As shown in Figure 4B , VSV-N was detected at day 2 in tumor (8 of 8), spleen (4 of 8), ovary (3 of 4), spinal cord (3 of 8), and blood (6 of 11) samples, whereas in other organs the virus was not detected. At day 28 or 29 after treatment, the virus was not detected (only tissues that were positive on day 2 were tested), except for 1 tumor sample.
Similar results were observed in tumor-bearing rats treated with VSV-h-IFN-b ( Figure 5 ). Rats (n 5 6 per group) were treated with 1 3 10 8 or 1 3 10 9 TCID 50 VSV-h-IFN-b and followed out either 2 days or 1 month for the highest dose. No signs of general toxicity or neurotoxicity were observed throughout the study, and no treatment-related deaths were observed. Infectious virus was detected in 5 of 6 tumor samples, and in none of the brain or spleen tissues at day 2 in rats treated with 1 3 10 9 TCID 50 VSV-h-IFN-b ( Figure 5A ). Viral RNA was detected at day 2 in tumor (6 of 6), spleen (5 of 6), ovary (3 of 3), spinal cord (1 of 6), and blood (4 of 9). Virus in the spleen was detected at or below the LOQ ( Figure 5B ).
Additional studies were performed in non-tumorbearing rats, which were treated with a single subcutaneous (below the jaw line) injection of escalating doses Blood was obtained for hematological and biochemical studies to assess whether VSV treatment is associated with hematological, renal, or hepatic toxicity. No clinically significant differences between tumor or non-tumor-bearing treated and control rats were detected (data not shown).
Antibody production
Blood from tumor-bearing and tumor-free rats treated with the rat or human IFN expressing VSV vectors was obtained at days 2 and 28 or 29 of treatment for determination of serum anti-VSV antibody by enzyme-linked immunosorbent assay (ELISA). Anti-VSV antibody was not detected from day 2 serum (not shown), whereas a dose-dependent increase in antibody titers was observed at day 28 or 29 in tumor-bearing rats treated with the rat (Figure 4C ) or human ( Figure 5C ) VSV-IFN-b. Likewise, a robust (anti-VSV) antibody response was observed in non-tumor-bearing rats at day 28 or 29 after treatment in all dose levels (data not shown).
In vivo antitumor effects of vesicular stomatitis virus-rat-interferon-b and vesicular stomatitis virus-human-interferon-b
The FAT-7 model was established, as outlined in the Materials and Methods section. After tumors reached , and 5 3 10 9 PFUs) were administered and changes in tumor volume were assessed. Rats treated with a dose of 5 3 10 8 PFUs had a significant delay in tumor growth (p < .0001 at day 43; Figure 6A ), as well as time to euthanization (p 5 .0008; Figure 6B ) compared with controls. Interestingly, rats treated at a higher dose (5 3 10 9 PFU) did not have additional benefit in tumor reduction or time to euthanization. Next, we determined the effects of single versus 2 intratumoral injections of VSV-r-IFN-b (at a dose of 5 3 10 8 PFU) as well as the effects of IV administration of the virus (1 dose of 5 3 10 8 PFU) in tumorbearing rats. Treatment with 1 or 2 intratumoral doses or 1 IV dose of VSV-r-IFN-b was associated with significant delay in tumor growth (p < .0001 at day 43; Figure  6C ), and improvement in time to euthanization (p < .05; Figure 6D ) compared with controls.
Finally, we investigated the effects of VSV-h-IFN-b in the syngeneic model. Tumor-bearing rats were treated with either intratumorally or IV VSV-h-IFN-b (1 dose of 5 3 10 8 PFUs) around day 21 after tumor implantation. As shown in Figure 7A and 7B, both intratumorally and IV administration of VSV-h-IFN-b were associated with significant tumor delaying effects (p 5 .0002 VSVintratumoral vs control; p 5 .0004, VSV-IV vs control at day 38), as well as improved survival (time to euthanization) compared with mock treated animals (p < .0001). No significant toxicity was observed in VSV-h-IFN-btreated animals.
DISCUSSION
Significant progress has been made in the field of oncolytic virotherapy, with an increasing number of oncolytic viral vectors showing promising antitumor activity and entering phase III clinical studies. SCC of the head and neck is an ideal model for the development of oncolytic virotherapy strategies because: (1) recurrent disease at the primary site or in the neck is common after initial therapy; (2) the recurrent disease is most often accessible for local injection of the vector; and (3) outcomes are poor with the limited therapeutic options available for these patients.
VSV is a potent oncolytic agent that has shown antitumor effects in several tumor types in vitro and in vivo, including SCC of the head and neck. 13, 15, 18, 23, [30] [31] [32] [33] [34] VSV-IFN-b is a second generation recombinant oncolytic VSV that has an improved safety window, as previously reported. 18 In this report, we provided preclinical evidence of the safety and activity of VSV-IFN-b in an immunocompetent, syngeneic rat model of head and neck SCC.
In vitro cytotoxicity and viral replication were demonstrated in murine and rat SCC cell lines, and transgene expression of IFN-b was confirmed in the above cell lines after infection with species-specific VSV-IFN-b. The cytotoxic effects of VSV-IFN-b were not significantly affected by hypoxia, which provides a potential therapeutic advantage as hypoxia is a common feature of advanced head and neck tumors and is associated with poor prognosis. [35] [36] [37] Administration of both intratumoral or IV VSV-h-IFN-b or VSV-r-IFN-b was found to be safe. No significant toxicity or treatment-related deaths were observed in the rats treated with either rat or human VSV-IFN-b. Because we are proposing a phase I clinical trial to investigate safety of intratumoral administration of VSV-h-IFN-b virus in patients with advanced refractory head and neck cancer, our preclinical studies focused mainly on intratumoral administration of virus in rats bearing SCC tumors in the neck area. No significant toxicity was seen in rats treated at doses up to 10 10 TCID 50 of VSV-r-IFN-b and up to 10 9 TCID 50 of VSV-h-IFN-b. Based on the above results, the NOAEL was determined to be 10 10 TCID 50 VSV-r-IFN-b when delivered intratumorally in Fischer-344 rats, either tumor-free or those bearing the head and neck SCC tumor FAT-7 s.c. For in vivo experiments using VSV-h-IFN-b, the NOAEL in tumor and non-tumor-bearing rats was determined to be 1 3 10 9 TCID 50 . The data presented in the current study further support the preclinical safety profile of this virus, as previously reported in other models. 18, 21 Biodistribution studies demonstrated higher levels of VSV-IFN-b (human or rat) RNA (by qRT-PCR) in tumors, compared to non-tumor-bearing tissues, such as spleen, ovary, and blood. Viable viral particles, however, were recovered only in tumor-bearing organs, suggesting that although VSV-IFN-b may transiently infect both tumor and non-tumor tissues, viral replication and cytotoxic effects occur predominantly in tumors because of the protective antiviral effects of virus-induced IFN-b expression in normal tissues. No clinically significant hematological or biochemical side effects were observed in treated rats, which correlate well with lack of systemic toxicity or treatment-related deaths in our studies. As expected, antibody formation was detected at day 28 or 29, in a dose-dependent manner.
In vivo, both VSV-r-IFN-b and VSV-h-IFN-b were associated with significant delays in progression in rats bearing aggressive FAT-7 tumors. We saw no significant differences in the antitumor effects between intratumoral versus IV administration of 1 dose of virus, or significant differences in antitumor effects between 1 versus 2 intratumoral administrations of VSV-r-IFN-b. We did not observe tumor eradication after intratumoral or IV treatment. This may be because of the development of host antiviral immunity, which prevented prolonged viral replication. However, the observed effects were associated with improvement in survival in the treated rats.
In conclusion, intratumoral administration of VSV-r-IFN-b or VSV-h-IFN-b in immunocompetent rats bearing syngeneic SCC tumors was feasible and safe at the doses tested. The safety and efficacy of VSV-IFN-b in this syngeneic model showed in this report provides a preclinical rationale for the clinical evaluation of this viral vector in human SCC of the head and neck. Further characterization of VSV-IFN-b biodistribution after systemic administration and repeated administration in vivo are underway, as well as the first human phase I trial of VSV-h-IFN-b in human SCC of the head and neck.
